On-body Drug Delivery Devices Market to Reach US$ 796.1 Million Valuation by 2034, Growing at 6.8% CAGR: TMR Report

Companies in the on-body drug delivery devices market are working toward launching more efficient on-body delivery systems for injectables. They are also exploring the launch of multifunctional system in order to send drugs where they could be effective in the body's organs and tissues

WILMINGTON, Del., Aug. 2, 2024 /PRNewswire/ -- The on-body drug delivery devices market is poised to expand at a CAGR of 6.8% from 2024 to 2034. By the end of the aforementioned forecast period, the market is poised to total US$ 796.1 million in value terms. A basic advantage of an on-body drug delivery device is that it is able to accurately target specific cells and tissues. This minimizes the side-effects of drugs and increase therapeutic efficacy.

https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg

An on-body drug delivery device is a patched-on device delivering big molecules (biologics) subcutaneously and has been designed for therapies that periodically need a specific quantity of formulated drug. Typical applications comprise proteins such as monoclonal antibodies (mAbs).

The advantages offered by on-body drug delivery devices include higher level of precision at lower dosing increments, home-use with bolus and/or basal profile, automatic needle insertion and retraction, occlusion detection, resusable/disposable concept supporting sustainability, and use of standard glass cartridges. Research states that targeted drug delivery results in enhanced pharmacokinetics such as improved absorption, distribution, metabolism, and excretion (ADME).

Request a PDF Sample of this Report Now! https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=84069

Increasing preference for advanced drug delivery systems has widened the scope for on-body drug delivery devices. Advanced drug delivery technologies have proven to enhance treatment outcomes in various ways, which include enhancement of therapeutic efficacy, increasing patient compliance, reducing toxicity, and facilitating novel medical treatments.

Key Takeaways from the Market Study

    --  The market for on-body drug delivery is poised to accumulate a value of
        US$ 416.8 million in 2024.
    --  The on-body drug delivery devices market is poised for a 1.9x growth
        from 2024 to 2034.
    --  By application, cancer is expected to emerge as an important area for
        on-body drug delivery devices use.
    --  By product type, both wearable and auto-injectors are expected to enjoy
        heightened demand throughout the forecast period.
    --  Hospitals are the main sites for availing on-body drug delivery devices
        for patients.

Key Market Drivers and Trends

    --  On-body drug delivery devices help in obtaining enhanced drug safety
        along with patient compliance. These devices are designed such that
        therapeutic levels of drug are maintained, and side-effects and overdose
        of drugs can be reduced. Besides, drugs can be delivered with short
        in-vivo half-lives.
    --  Targeted drug delivery systems such as on-body drug delivery devices are
        capable of concentrating a medicine's active ingredient at site of a
        lesion/anatomical target. This keeps the drug at effective concentration
        on targeted organs for a longer duration, facilitating prescription of
        medicines at a lower dose.

On-body Drug Delivery Devices Market Report Scope:



     
              Report Coverage 
     
              Details



     Forecast Period            
     2024-2034



     Base Year                  
     2020-2022



     Size in 2023               
     US$ 390.7 Mn



     Forecast (Value) in 2034   
     US$ 796.1 Mn



     Growth Rate (CAGR)                                         6.8 %



     No. of Pages               
     136 Pages



     Segments covered             By Product Type, By Application, By
                                    End-user

Unlock Growth Potential in Your Industry! Download PDF Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=84069

Regional Profile

    --  North America expects to witness substantial progress with respect to
        on-body drug delivery devices sales. This is attributed to growing
        demand for advanced drug delivery systems such as metered-dose inhalers
        and sensor-embedded devices. As per a study published by CIHI in April
        2021, more than 3 million acute inpatient hospitalizations were
        witnessed in Canada from 2019 to 2020.
    --  The market in Europe is expected to see substantial expansion. Europe's
        market growth is ascribed to rise in awareness about advanced drug
        delivery devices and rise in adoption of the advanced products.
    --  Various clinical trials are being conducted regularly for novel products
        and introduction of new products by the key participants. Along these
        lines, in April 2021, Medtronic launched its extended infusion set in
        select European nations. It can be worn for close to a week.

Competitive Landscape

Key participants in the on-body drug delivery devices market are launching new products to strengthen their position. For instance, in September 2023, Corium, Inc. introduced ADLARITY, a donepezil transdermal system in the U.S. to treat patients contracting mile-to-severe Alzheimer's.

In August 2022, Baxter announced that it had obtained clearance from the U.S. FDA for usage of Novum IQ Syringe Infusion Pump with Dose IQ Safety Software. These infusion pumps deliver small quantities of fluid at low rates in neonatal, pediatric, or anesthesia care settings with utmost precision.

Enable Injections Inc., NOVO Engineering, Elcam Medical, Battelle, and Gerresheimer AG are some of the key players covered in the on-body drug delivery devices market report.

Key Players Profiled

    --  Enable Injections Inc.
    --  NOVO Engineering
    --  Elcam Medical
    --  Battelle
    --  Gerresheimer AG

Recent Market Developments

    --  In January 2024, Medtronic received CE Mark approval for MiniMed 780G
        system, in collaboration with Simplera Sync. MiniMed 780G is one of the
        automated insulin delivery system, which is equipped with meal detection
        technology and makes provision for automatic adjustments as well as
        corrections to the levels of sugar every five minutes.
    --  In February 2023, Innovation Zed received CE mark for its InsulCheck
        DOSE, one of the single unit add-on device for insulin pen injectors.

Key Segments Profiled

Product Type

    --  Wearable Injectors
    --  Auto-injectors
    --  Patches
    --  Others

Application

    --  Cardiovascular Diseases
    --  Cancer
    --  Autoimmune Diseases
    --  Diabetes
    --  Others (Orthopedic Disorders, etc.)

End User

    --  Hospitals
    --  Specialty Clinics
    --  Ambulatory Surgery Centers
    --  Others (Research Institutes, etc.)

Region

    --  North America
    --  Europe
    --  Asia Pacific
    --  Latin America
    --  Middle East & Africa

Purchase the Report for Market-Driven Insights: https://www.transparencymarketresearch.com/checkout.php?rep_id=84069&ltype=S

More Trending Report by Transparency Market Research:

    --  Mechanical Thrombectomy Devices Market - In 2022, the Mechanical
        Thrombectomy Devices market was valued at USD 1.1 billion. It is
        projected to grow at a CAGR of 6.4% from 2023 to 2031, reaching over USD
        1.8 billion by the end of 2031.
    --  Sanitization Robots Market - The Sanitization Robots market was valued
        at USD 927.3 million in 2022 and is anticipated to grow at a remarkable
        CAGR of 19.2% from 2023 to 2031. By 2031, the market is expected to
        surpass USD 4.8 billion.
    --  Microcatheter Market - Valued at USD 799.7 million in 2022, the
        Microcatheter market is estimated to grow at a CAGR of 5.3% from 2023 to
        2031. This growth is projected to elevate the market value to USD 1.3
        billion by the end of 2031.
    --  Infant Resuscitators Market - The global Infant Resuscitators market,
        valued at USD 253.1 million in 2022, is expected to grow at a compound
        annual growth rate (CAGR) of 5.2% from 2023 to 2031. This growth is
        projected to increase the market value to over USD 401.4 million by the
        end of 2031.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com

Follow Us: LinkedIn| Twitter| Blog | YouTube

Logo: https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/on-body-drug-delivery-devices-market-to-reach-us-796-1-million-valuation-by-2034--growing-at-6-8-cagr-tmr-report-302213339.html

SOURCE Transparency Market Research